title: Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim?
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Ferretti
authors.forename: Massimo
authors.initials: M
authors.lastname: Lopez
authors.forename: Edmondo
authors.initials: E
authors.lastname: Terzoli
authors.forename: Enrico
authors.initials: E
authors.lastname: Cortesi
authors.forename: Mauro
authors.initials: M
authors.lastname: Antimi
authors.forename: Paolo
authors.initials: P
authors.lastname: Marolla
authors.forename: Diana
authors.initials: D
authors.lastname: Giannarelli
authors.forename: Francesco
authors.initials: F
authors.lastname: Cognetti
authors.forename: Paola
authors.initials: P
authors.lastname: Papaldo
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005334:Fever / Q000517:prevention & control; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D007964:Leukocytosis / Q000139:chemically induced / Q000517:prevention & control*; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D015251:Epirubicin; D003520:Cyclophosphamide; D000069585:Filgrastim